Unlabelled: Bis(N-ethoxy,N-ethyldithiocarbamato)nitrido technetium (V) ((99m)Tc) ((99m)TcN-NOET) is a new myocardial perfusion imaging agent currently undergoing phase III clinical trials in the United States and in Europe. (99m)TcN-NOET cellular uptake has been shown to be inhibited by the calcium channel inhibitor verapamil in cultured newborn rat cardiomyocytes. However, the effect of verapamil on in situ (99m)TcN-NOET myocardial uptake remains unknown. Therefore, the aim of this study was to evaluate whether the inhibitory effect of verapamil on the cellular uptake of (99m)TcN-NOET shown in vitro could be reproduced in situ in a canine model of normal and ischemic myocardium.
Methods: (99m)TcN-NOET uptake in normal and ischemic myocardium (70% flow reduction in the left anterior descending coronary artery) was measured in the absence or presence of verapamil (0.015 mg/kg/min x 10 min) in anesthetized, open-chest dogs (n = 17). Control animals were infused with adenosine (0.2 mg/kg/min) to match the verapamil-induced increase in flow.
Results: By verapamil treatment, a clinically relevant plasma concentration of the calcium channel inhibitor was attained (mean +/- SEM, 290 +/- 152 ng/mL). In normal myocardium (n = 8), regional blood flow at the time of (99m)TcN-NOET injection was not statistically different in verapamil- and adenosine-treated dogs (1.69 +/- 0.03 vs. 1.61 +/- 0.04 mL/min/g, respectively). (99m)TcN-NOET uptake was slightly higher in the presence of verapamil (0.39 +/- 0.01 vs. 0.38 +/- 0.01 counts per minute [cpm]/[Bq/kg]/g for adenosine; P = 0.04). However, no significant difference in (99m)TcN-NOET myocardial uptake was observed after normalization of the tracer uptake to regional myocardial blood flow. In ischemic myocardium (n = 9), regional blood flow was lower in verapamil-treated than in adenosine-treated animals (0.22 +/- 0.02 vs. 0.29 +/- 0.03 mL/min/g; P < 0.05). (99m)TcN-NOET uptake in the ischemic area was not inhibited by verapamil (0.09 +/- 0.01 vs. 0.10 +/- 0.01 cpm/[Bq/kg]/g; P = not significant).
Conclusion: Verapamil does not inhibit (99m)TcN-NOET uptake in situ in normal and ischemic canine myocardium. These results suggest that verapamil should not affect (99m)TcN-NOET myocardial uptake in patients referred for myocardial perfusion imaging.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Comparative study of uptake and washout of 99mTcn(NOEt)2 with 99mTc-MIBI in human nasopharyngeal carcinoma cell line CNE].
Lin Chuang Er Bi Yan Hou Ke Za Zhi
September 2006
Department of Otorhinolaryngology, Union Hospital of Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To determine the cellular kinetics of 99mTc-bis {N-ethoxy-N-ethyl dithiocarbamato-nitrido [N(NOEt)2]} in human nasopharyngeal carcinoma CNE cells line and to compare it with the cellular kinetics of 99mTc-methoxyisobutylisonitrile (MIBI) in the same conditions; to define the possible clinical application value of 99mTcN(NOEt)2 in nasopharyngeal carcinoma imaging.
Method: 99mTcN(NOEt)2 or 99mTc-MIBI were incubated with CNE cells at 37degrees C, 22 degrees C, at different time points after incubation, the uptake and washout characteristics of radiotracers in CNE cells were investigated and compared.
Result: The maximum uptake ratio of 99mTcN(NOEt)2 in CNE cells was 43.
99mTcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents.
Nucl Med Commun
November 2005
Medical and Biological Products Program, Board of Radiation and Isotope Technology, Mumbai, 400094, India.
Objective: Two ligands viz. tert-butyl dithiocarbamate (TBDTC) and methoxyisobutyl dithiocarbamate (MIBDTC), which are analogous to the tert-butyl isonitrile (TBI) and sestamibi (MIBI) ligands, were synthesized and labelled with the [99mTcN] core to evaluate their potential as myocardial agents. As these complexes have low molecular weights, and are neutral and lipophilic in nature, they have a tendency to cross the blood-brain barrier and thus deserve evaluation as potential brain perfusion imaging agents.
View Article and Find Full Text PDFVerapamil does not inhibit 99mTcN-NOET uptake in situ in normal or ischemic canine myocardium.
J Nucl Med
June 2003
Laboratoire d'Etude de Radiopharmaceutiques, University Hospital of Grenoble, Grenoble, France.
Unlabelled: Bis(N-ethoxy,N-ethyldithiocarbamato)nitrido technetium (V) ((99m)Tc) ((99m)TcN-NOET) is a new myocardial perfusion imaging agent currently undergoing phase III clinical trials in the United States and in Europe. (99m)TcN-NOET cellular uptake has been shown to be inhibited by the calcium channel inhibitor verapamil in cultured newborn rat cardiomyocytes. However, the effect of verapamil on in situ (99m)TcN-NOET myocardial uptake remains unknown.
View Article and Find Full Text PDFBiodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTcN-NOET in healthy volunteers.
J Nucl Med
January 2000
Faculté de Médecine, Université de Grenoble, France.
Unlabelled: 99mTcN-NOET (bis[N-ethoxy,N-ethyl]dithiocarbamato nitrido technetium (V)) has been proposed for myocardial perfusion imaging. Biodistribution, safety, and dosimetry were studied in 10 healthy volunteers (5 at rest and 5 during exercise).
Methods: Biodistribution was studied by acquiring dynamic images up to 60 min after injection and whole-body images up to 24 h after injection.
Objective: The biological properties of a new neutral myocardial imaging agent 99mTcN(NOEt)2 were evaluated.
Methods: Blood clearance in rabbits, biodistribution in rats, and initial myocardial imaging in dogs were performed.
Results: Radiochemical purity of 99mTcN(NOEt)2 was more than 90% and stable for 6 h at room temperature.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!